Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice

• Үндсэн зохиолчид: Yilin Chen (Зохиогч), Huifang Zhao (Зохиогч), Jingming Guo (Зохиогч), Jing Zou (Зохиогч), Wenjuan He (Зохиогч), Danlei Han (Зохиогч), Fanjun Cheng (Зохиогч), Yanli Zhang (Зохиогч), Weiming Li (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background: In clinical studies, some patients who achieve deep molecular response (DMR) can successfully discontinue tyrosine kinase inhibitor (TKI). TKI dose reduction is also an important aspect of alleviating adverse effects and improving quality of life. This study aimed to explore the outcome...